Clinical TrialJul 2, 2026, 08:02 AM
Revolution Medicines' Zoldonrasib Shows Positive Phase 1/2 Pancreatic Cancer Results
AI Summary
Revolution Medicines announced positive Phase 1/2 clinical trial results for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The zoldonrasib plus chemotherapy regimen in previously untreated patients demonstrated compelling antitumor activity, with an 82% objective response rate (ORR) with mFFX and 61% with GnP. The zoldonrasib plus daraxonrasib combination in previously treated patients achieved a 50% ORR in the second-line cohort and 47% in the third-line-plus cohort, with promising progression-free survival. These findings support the ongoing RASolute 305 and planned RASolute 309 Phase 3 trials.
Key Highlights
- Zoldonrasib + mFFX in first-line PDAC showed 82% ORR and 96% DCR.
- Zoldonrasib + GnP in first-line PDAC showed 61% ORR and 90% DCR.
- Zoldonrasib + daraxonrasib in second-line PDAC achieved 50% ORR and 9.6 months median PFS.
- Zoldonrasib + daraxonrasib in third-line+ PDAC achieved 47% ORR and 7.6 months median PFS.
- Grade 3+ TRAEs were 61% for zoldonrasib + mFFX and 80% for zoldonrasib + GnP.
- Grade 3+ TRAEs for zoldonrasib + daraxonrasib were 35%.
- Results support ongoing RASolute 305 and planned RASolute 309 Phase 3 trials.
Price Impact
More from RVMD